Ensign Peak Advisors, Inc Beam Therapeutics Inc. Transaction History

Ensign Peak Advisors, Inc

$51.2 Billion
Q1 2025

A detailed history of Ensign Peak Advisors, Inc transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 29,111 shares of BEAM stock, worth $749,608. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,111

Previous 29,111 -0.0%

Holding current value

$749,608

Previous $721,000 21.22%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$23.46 - $45.07 $34,462 - $66,207	-1,469 Reduced 4.8%	29,111 $961,000
Q2 2023 Aug 14, 2023	BUY	$29.32 - $35.99 $65,970 - $80,977	2,250 Added 7.94%	30,580 $976,000
Q1 2023 May 15, 2023	BUY	$30.15 - $48.79 $84,420 - $136,612	2,800 Added 10.97%	28,330 $867,000
Q4 2022 Feb 13, 2023	BUY	$36.73 - $51.6 $433,413 - $608,880	11,800 Added 85.94%	25,530 $998,000
Q3 2022 Nov 14, 2022	SELL	$39.79 - $70.31 $2.42 Million - $4.27 Million	-60,757 Reduced 81.57%	13,730 $654,000
Q2 2022 Aug 12, 2022	BUY	$29.86 - $62.36 $1.97 Million - $4.12 Million	66,047 Added 782.55%	74,487 $2.88 Million
Q4 2021 Feb 11, 2022	SELL	$68.02 - $99.06 $1.26 Million - $1.84 Million	-18,594 Reduced 68.78%	8,440 $673,000
Q1 2021 May 12, 2021	SELL	$71.28 - $120.75 $6.65 Million - $11.3 Million	-93,273 Reduced 77.53%	27,034 $2.16 Million
Q4 2020 Feb 12, 2021	BUY	$22.24 - $95.63 $1.21 Million - $5.21 Million	54,489 Added 82.79%	120,307 $9.82 Million
Q3 2020 Nov 12, 2020	BUY	$19.0 - $30.57 $709,954 - $1.14 Million	37,366 Added 131.33%	65,818 $1.62 Million
Q2 2020 Aug 12, 2020	SELL	$15.26 - $28.66 $93,910 - $176,373	-6,154 Reduced 17.78%	28,452 $797,000
Q1 2020 May 11, 2020	BUY	$13.31 - $29.2 $460,605 - $1.01 Million	34,606 New	34,606 $623,000

Others Institutions Holding BEAM

# of Institutions

247

Shares Held

95.7M

Call Options Held

666K

Put Options Held

1.99M

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.81B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.

Account

Ensign Peak Advisors, Inc Beam Therapeutics Inc. Transaction History